噻托溴铵治疗尘肺Ⅰ期合并中重度慢性阻塞性肺疾病稳定期患者的效果分析

Analysis on the Effect of Tiotropium Bromide for the Treatment of Phase Ⅰ Pneumoconiosis Complicated with Moderate or Severe Stable Phase COPD

目的探讨噻托溴铵治疗尘肺Ⅰ期合并中重度慢性阻塞性肺疾病(COPD)稳定期患者的效果。方法选取我院收治的尘肺I期合并中重度COPD稳定期患者90例,随机分为两组各45例。两组均采用常规治疗,观察组在常规治疗基础上实施吸入噻托溴铵粉雾剂治疗,对照组在常规治疗基础上实施吸入异丙托溴胺气雾剂治疗,观察两组的临床治疗效果。结果治疗后,观察组患者的COPD急性发作次数显著少于对照组,FEV_1%、FVC、TLC均显著优于对照组,差异均有统计学意义(P<0.05)。结论尘肺Ⅰ期合并中重度COPD稳定期患者应用噻托溴铵粉雾剂治疗可有效降低患者的疾病急性发作次数,改善患者肺功能。

Objective To explore the effect of tiotropium bromide for the treatment of patients with phase I pneumoconiosis complicated with moderate or severe stable phase COPD. Methods＇ 90 cases of patients with phase I pneumoconiosis complicated with moderate or severe stable phase COPD admitted to our hospital were selected and randomly divided into two groups, with 45 cases in each group. All patients received routine therapy; in addition, the control group was treated with ipratropium bromide aerosol for inhalation, and the observation group was treated with tiotropium bromide powder for inhalation. The clinical curative effects of two groups were observed. Results＇ After treatment, the times of COPD acute exacerbation of the observation group was significantly lower than that of the control group, and the FEV1%, FVC and TLC were significantly better than those of the control group （P〈0.05）. Conclusions Tiotropium bromide powder for the treatment of patients with phase I pneumoconiosis complicated with moderate or severe stable phase COPD can effectively reduce the times of disease acute exacerbation, and improve patients＇ lung function.